Best hospitals for Bone Marrow Transplantation: An Evidence-Based Review

How hospitals are evaluated

Bone marrow transplantation is more accurately described as hematopoietic stem cell transplantation, or HSCT. The treatment replaces unhealthy or damaged blood-forming cells with healthy stem cells and may be used for selected blood cancers, marrow disorders, immune conditions, and some non-malignant diseases. Hospital selection depends on disease-specific experience, transplant type, donor services, infection prevention, accreditation, and long-term follow-up rather than on a simple universal ranking. 1

Reported outcomes also require careful interpretation. The Center for International Blood and Marrow Transplant Research, or CIBMTR, compares one-year allogeneic transplant survival with national risk-adjusted expectations. Such results reflect patient risk, disease status, transplant method, and follow-up practices, so a published performance distinction should inform discussion with a specialist rather than function as a guarantee for an individual patient. 2

Ten prominent hospitals and programs

The research identifies several established United States programs, alongside internationally recognized centers, that are frequently considered for complex transplantation. The following list is not a universal ranking. It summarizes documented institutional strengths and areas of activity described in the supplied material. 1

Programs with reported outcome data

The USC Norris Blood and Marrow Transplant and Cell Therapy Program reported the highest possible plus-one performance score in a 2025 CIBMTR analysis of 176 United States transplant programs. The program reported an 86% one-year allogeneic transplant survival rate and was described as one of only four programs to achieve the distinction for six consecutive years. 2

Cedars-Sinai reported that its donor stem cell transplant outcomes for blood cancers were significantly better than predicted for six consecutive years. Its program was identified as one of seven adult centers among 176 United States programs with significantly better-than-predicted survival, while a separate institutional report described one-year transplant survival reaching 90%. These figures are center-level results, not individual forecasts. 37

International options and specialist capabilities

Saint-Louis Hospital in Paris operates a JACIE-accredited hematology transplant unit dedicated to allogeneic HSCT for malignant hematologic disorders, with particular expertise in myeloid diseases. The unit also treats aplastic anemia, paroxysmal nocturnal hemoglobinuria, constitutional neutropenia, leukemias, lymphomas, myelodysplastic syndromes, and myeloproliferative neoplasms. 4

Sheba Medical Center in Israel describes a program combining precision genetic diagnostics, haploidentical transplantation, and in-house CAR-T manufacturing. Maisonneuve-Rosemont Hospital in Montreal reports internationally recognized expertise and a dedicated pavilion containing 36 specialized isolation rooms. These examples show how hospitals may differentiate themselves through laboratory infrastructure, donor-matching approaches, cellular therapy, and protected inpatient capacity. 58

Accreditation, volume, and service scope

Accreditation can provide evidence that a program has undergone external review of quality systems, although it does not eliminate medical risk. Ochsner LSU Health reports Foundation for the Accreditation of Cellular Therapy accreditation for autologous transplantation and describes itself as the only regional center offering autologous, allogeneic, and CAR-T services across its stated service area. 6

WVU Cancer Institute describes its Osborn Hematopoietic Malignancy and Transplantation Program as an accredited blood and marrow transplant program and reports an average of approximately 70 transplants each year. UCI Health reported completing its 400th hematopoietic stem cell procedure in 2026, after reaching 200 transplants by 2024, and described treatment for malignant and non-malignant diseases, including selected autoimmune conditions. 79

Eligibility, risks, and long-term realities

Transplant eligibility depends on the underlying disease, disease control, age, organ function, infection status, donor availability, and the proposed conditioning regimen. Transplants can provide cure or long-term disease control for selected patients, but they also carry risks including infection, toxicity, relapse, graft-versus-host disease, and complications affecting recovery. The supplied clinical material emphasizes that the first several months, particularly the first 100 days, require close monitoring. 13

Before choosing a hospital, patients and families should ask how the center manages donor searches, conditioning, graft-versus-host disease prevention, emergency complications, outpatient monitoring, fertility or organ concerns, rehabilitation, and survivorship. Long-term follow-up is essential because recovery varies widely. Some people live for decades after successful transplantation, but outcomes depend heavily on the original disease, relapse risk, complications, and continuing clinical management. 1

How to compare centers responsibly

A practical comparison should separate documented facts from reputation. Relevant questions include whether the program treats the specific disease, performs the required transplant type, offers unrelated or haploidentical donor pathways, provides CAR-T or clinical trials when appropriate, maintains recognized accreditation, and publishes risk-adjusted outcomes. The National Cancer Institute directory can help identify NCI-Designated Cancer Centers, which integrate cancer research and clinical care, but designation alone does not establish that a center is suitable for every transplant case. 10

• Confirm experience with the specific diagnosis and transplant approach.
• Review outcomes in patients with comparable disease risk and health status.
• Ask about infection control, donor coordination, and post-transplant monitoring.
• Clarify travel, caregiver, lodging, and communication requirements during recovery.
• Compare a center’s research access with the risks and eligibility rules of each study.

The strongest choice is therefore individualized rather than based solely on a national list. A center with high reported survival may not be the appropriate setting if it lacks experience with a rare condition, a needed donor strategy, pediatric or adult specialization, or the patient’s required cellular therapy. A hematologist and transplant team can interpret institutional data in relation to diagnosis, treatment history, and personal risk. 1

Sources

1. Acibadem Hospitals Group, “Top 10 Hospitals for Bone Marrow Transplant USA”
2. Keck Medicine of USC, “Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes”
3. Cedars-Sinai, “Cedars-Sinai Again Earns Top Stem Cell Transplant Ranking”
4. Institut de la Leucémie, Saint-Louis Hospital Hematology Transplant Unit
5. Sheba Medical Center, “Sheba Is Advancing Bone Marrow Transplantation and Cellular Therapy”
6. Ochsner LSU Health, Blood and Marrow Transplant and Cellular Therapy Program
7. WVU Cancer Institute, Blood and Marrow Transplants
8. Université de Montréal, “Stem cells: saving lives by building a new immune system”
9. UCI Health, “UCI Health completes 400th successful stem cell procedure”
10. National Cancer Institute, NCI-Designated Cancer Centers directory